Back to news

PacBio Slides as Recent Rally Cools and Investors Reassess Turnaround Risks

Investivoq PriceTracker

Pacific Biosciences of California, Inc. (PACB) is down 6.1% today. Here is some analysis on what might have caused this price movement.

Analysis: A clear single-day catalyst is hard to pin down, so the move appears most likely tied to profit-taking after PACB’s sharp late-September and early-October rally. This could be because investors are balancing recent product and ecosystem announcements against PacBio’s still-fragile financial profile, restructuring efforts, leadership transition, and cautious analyst sentiment.

Details:

  • PACB had surged in the sessions leading into October 6, including a roughly 29.5% jump on September 30 and another 13.0% gain on October 5, creating conditions for a pullback after a very fast run.
  • PacBio recently benefited from fresh commercialization momentum, including the launch of EpiSign METRIC 5-base for use with PacBio HiFi sequencing and the ongoing rollout of SPRQ-Nx chemistry for the Vega system.
  • The company’s most recent quarterly disclosures also showed ongoing restructuring, including a workforce reduction of about 40 employees, with a goal of lowering annualized operating expenses by $30 million to $40 million by the end of 2027.
  • Investors are also still digesting management change after Mark Van Oene was appointed chief executive officer in August, while outside analyst coverage remains tilted toward hold-or-sell views rather than broad bullish upgrades.

    • Sources:

    PacBio, SEC, MarketBeat

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $PACB Insider Trading Activity

    PACB Insider Trades

    $PACB insiders have traded $PACB stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $PACB stock by insiders over the last 6 months:

    • OENE MARK VAN (See Remarks) sold 26,911 shares for an estimated $30,409

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive PACB Data Alerts
    Get market-moving data, filings, and signals for PACB in real time.
    Sign Up

    $PACB Hedge Fund Activity

    We have seen 86 institutional investors add shares of $PACB stock to their portfolio, and 106 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • BLACKROCK, INC. added 7,072,121 shares (+28.0%) to their portfolio in Q2 2026, for an estimated $11,881,163
    • ARK INVESTMENT MANAGEMENT LLC removed 6,491,872 shares (-17.9%) from their portfolio in Q2 2026, for an estimated $10,906,344
    • POINT72 ASSET MANAGEMENT, L.P. added 4,501,600 shares (+1575.6%) to their portfolio in Q2 2026, for an estimated $7,562,688
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,652,298 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,455,860
    • GOLDMAN SACHS GROUP INC added 2,241,420 shares (+226.8%) to their portfolio in Q2 2026, for an estimated $3,765,585
    • LONGAEVA PARTNERS L.P. added 2,118,231 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,558,628
    • NUVEEN, LLC removed 1,927,816 shares (-65.3%) from their portfolio in Q2 2026, for an estimated $3,238,730

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $PACB Government Contracts

    We have seen $1,868,871 of award payments to $PACB over the last year.

    Here are some of the awards which we have have seen pay out the most over the last year:

    • LONG-READ SEQUENCING REAGENTS OF WHOLE GENOME ANALYSES: $240,215
    • REVIO SERVICE CONTRACT - PRODUCT CODE 102-873-100 - SERIAL NUMBER 84124: $85,000
    • THE NISC LABORATORY SUPPLIES STATE OF THE ART SEQUENCING SERVICES TO INSTITUTES THROUGHOUT THE NIH. THE HIG...: $85,000
    • SERVICE CONTRACT FOR PACBIO REVIO: $83,487

    To track government contracts to publicy traded companies, check out Investivoq's government contracts dashboard. You can access data on government contracts through the Investivoq API government contracts endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.